FIELD: medicine.
SUBSTANCE: present invention relates to immunology. Isolated antibodies and their antigen-binding fragments are proposed, binding CD30L (CD153) and characterized by the amino acid sequences of the hypervariable regions (CDRs) and variable domains. Pharmaceutical composition is described as well as a method for treating or preventing a pathological condition caused by CD30L, and a method of reducing CD30L activity in a patient. In addition, an isolated nucleic acid encoding an antibody or antigen-binding fragment and a host cell thereof are provided. Antibodies and antigen-binding fragments of the present invention provide inhibition of interaction of CD30L with CD30 and therefore can be further used in therapy.
EFFECT: use of antibodies and antigen-binding fragments for reducing activity of CD30L in a patient, and also for the treatment of inflammatory diseases, such as autoimmune diseases.
17 cl, 1 dwg, 8 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR SELECTION AND OBTAINING OF HIGHLY SELECTIVE AND MULTISPECIFIC TARGETING GROUPS WITH SPECIFIED PROPERTIES, INCLUDING AT LEAST TWO DIFFERENT BINDING GROUPS, AND THEIR APPLICATIONS | 2013 |
|
RU2639287C2 |
| ANTI-PDL-1 ANTIBODY, ITS PHARMACEUTICAL COMPOSITION AND USE | 2017 |
|
RU2693661C2 |
| CANINISED MURINE ANTIBODIES TO HUMAN PD-1 | 2014 |
|
RU2676158C1 |
| MONOVALENT CARRIER MODULES ACROSS BLOOD-BRAIN BARRIER | 2014 |
|
RU2694659C2 |
| UNIVERSAL TRANSMITTER MODULES THROUGH THE HEMATOENCEPHALITIC BARRIER | 2014 |
|
RU2799436C1 |
| ANTIGEN BINDING PROTEIN AND USE THEREOF AS ADDRESSING PRODUCT FOR TREATMENT OF CANCER | 2012 |
|
RU2659094C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROTEIN 1 OF PROGRAMMED CELL DEATH (PD-1) | 2017 |
|
RU2768404C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
| BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE | 2012 |
|
RU2605390C2 |
| ANTIBODIES AGAINST G-CSFR AND USE THEREOF | 2012 |
|
RU2605595C2 |
